SHINIL PHARMACEUTICAL CO., LTD. Q3 profit from main business KRW 1.4 billion, down 48.0% from a year earlier; sales KRW 23.8 billion
SAI summary · Not investment advice
Shinil Pharmaceutical sold KRW 23.8 billion worth in Q3 and earned KRW 1.4 billion from its main business, down 48.0% from a year earlier and 38.6% from the previous quarter.
Operating profit · 3 months
KRW 1.4 billion
Key facts
- Revenue (3 months)
- KRW 23.8 billion
- Net income (3 months)
- KRW 1.3 billion
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 20.6 billion
- Revenue (year to date)
- KRW 68.9 billion
- Operating profit (prior-year 3 months)
- KRW 2.7 billion
- Operating profit (year to date)
- KRW 5.0 billion
- Net income (prior-year 3 months)
- KRW 2.6 billion
- Net income (year to date)
- KRW 5.0 billion
Commentary
AI commentary · Not investment advice
What happened
Shin Il Pharmaceutical filed its quarterly report for the third quarter of 2026. On a standalone basis, sales for the 3 months were KRW 23.83 billion. That is 15.5% higher than the same 3 months a year earlier, which were KRW 20.62 billion.
In the company's terms
Operating profit (earnings from the main business) for the 3 months was KRW 1.39 billion. That is 48.0% lower than a year earlier, when it was KRW 2.67 billion. It is also 38.6% lower than the previous quarter. Net income (final profit after taxes) for the 3 months was KRW 1.35 billion. That is 48.3% lower than a year earlier and 39.9% lower than the previous quarter.
What changes for shareholders
For the year to date, from January to September, sales were KRW 68.89 billion. Operating profit was KRW 4.98 billion, and net income was KRW 5.03 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist